0001415889-24-011251.txt : 20240419 0001415889-24-011251.hdr.sgml : 20240419 20240419180015 ACCESSION NUMBER: 0001415889-24-011251 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240417 FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillies Hunter CENTRAL INDEX KEY: 0001868997 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24859100 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-04192024_060404.xml X0508 4 2024-04-17 0001798749 Aerovate Therapeutics, Inc. AVTE 0001868997 Gillies Hunter C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2024-04-17 4 M 0 4000 1.74 A 7251 D Common Stock 2024-04-17 4 S 0 3689 22.3006 D 3562 D Common Stock 2024-04-17 4 S 0 311 23.3277 D 3251 D Stock Option (Right to Buy) 1.74 2024-04-17 4 M 0 503 0 D 2030-09-03 Common Stock 503 2511 D Stock Option (Right to Buy) 1.74 2024-04-17 4 M 0 3497 0 D 2030-09-03 Common Stock 3497 539 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.08 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.12 to $23.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ George A. Eldridge, Attorney-in-Fact 2024-04-19